CLOs on the Move

Genentech

www.gene.com

 
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 35 years. At Genentech, we use human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Today, we are among the world`s leading biotech companies, with multiple products on the market and a promising development pipeline.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.gene.com
  • 1 DNA Way Mailstop 258A
    South San Francisco, CA USA 94080
  • Phone: 650.225.1000

Executives

Name Title Contact Details
Jinhee Chang
Intellectual Property Counsel Profile
Fred Medick
General Counsel Profile
Aviva Gilbert
Assistant General Counsel, Senior Profile
Yan Qi
Director and Assistant General Counsel, Platforms Profile
Sarah Tully
Director and Assistant General Counsel Profile

Similar Companies

Morphogenesis

Morphogenesis is a clinical stage company developing novel cell and gene therapies based on distinct and synergistic technology platforms. Our mission is to change the way chronic diseases are treated by engaging the innate intelligence of the body.

United Home Care Services

United Home Care Services, Inc. is a Miami, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Humanetics

Humanetics Corp. is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Xenobiotic Labs Inc

Xenobiotic Labs Inc is a Plainsboro, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Senda Biosciences

Senda Biosciences, Inc. is uniquely positioned to transform human health by harnessing millions of years of evolution to program targeted, potent and tunable medicines. Nature has provided the codes to program human cells – both within the cell (mRNA), and, remarkably, to the cell - using what surrounds it. The trillions of non-human cells in the human ecosystem have evolved natural nanoparticles that precisely shuttle biomolecules into human cells, providing the missing pieces to fully unlock programmable medicines. Senda`s proprietary platform includes the first-ever atlas of nature-derived programmable systems at the molecular level and across all kingdoms of life – accessing the entire code provided by nature required to program cells. With this platform, Senda is developing a new class of SendRNA™ medicines. The unique properties of these medicines create new frontiers for mRNA therapeutics and vaccines for infectious, genetic, autoimmune, and metabolic diseases and oncology indications – with further potential to transform the gene editing and protein-based therapy landscapes as well. Based in Cambridge, MA, Senda was founded by Flagship Pioneering.